# Imipramine on ER+ve and Triple Negative Breast Cancer

> **NCT03122444** · EARLY_PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 17 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Imipramine

## Key facts

- **NCT ID:** NCT03122444
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-05
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03122444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03122444, "Imipramine on ER+ve and Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03122444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*